Opinion

Aaron Goodman: My prediction (American Society of Hematology 2023)

Photo from Aaron Goodman/X

Dec 9, 2023, 16:37

Aaron Goodman: My prediction (American Society of Hematology 2023)

Aaron Goodman shared a post on X/Twitter:

“My prediction is the plenary session at American Society of Hematology in 2033 will be 10 drugs vs 9 drugs in myeloma end point Minimal Residual Disease (MRD). IKRd vs KRd in newly diagnosed multiple myeloma.

For details, click here.
Source: Aaron Goodman/X

Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.

Aaron Goodman American Society of Hematology cancer Minimal Residual Disease (MRD) multiple myeloma National Comprehensive Cancer Network OncoDaily Oncology University of California

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage